Tonix Pharmaceuticals Entered Agreement With Defense Threat Reduction Agency For $34M To Develop Broad-Spectrum Antiviral, TNX-4200, Through Phase 1 Clinical Evaluation
Tonix Pharmaceuticals Entered Agreement With Defense Threat Reduction Agency For $34M To Develop Broad-Spectrum Antiviral, TNX-4200, Through Phase 1 Clinical Evaluation
Tonix Pharmaceuticals與美國國防威脅緩解局達成協議，共計3400萬美元用於開發廣譜抗病毒藥物TNX-4200，通過第一階段臨床評估。
Tonix Pharmaceuticals Entered Agreement With Defense Threat Reduction Agency For $34M To Develop Broad-Spectrum Antiviral, TNX-4200, Through Phase 1 Clinical Evaluation
Tonix Pharmaceuticals與美國國防威脅緩解局達成協議，共計3400萬美元用於開發廣譜抗病毒藥物TNX-4200，通過第一階段臨床評估。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。